Morning stiffness could be a sign of arthritis, suggest study


https://speciality.medicaldialogues.in/morning-stiffness-could-be-a-sign-of-arthritis-suggest-study/

Castor Oil May Help Relieve Arthritis, Sciatica and Back Pain


You are probably aware that castor oil is regarded by some as a remedy for constipation remedy.

But you may not be aware of its reported use as an antiviral, antibacterial, and antifungal, or that it has been used topically to treat a variety of skin conditions, reduce pain, and stimulate your immune system.

Read on, because I’m about to explore the myth and mystery of this unusual oil, and of course, investigate what modern science has to say about it.

However, regardless of what some of the research has suggested, you should be very cautious when experimenting with castor oil since the science is sparse at best, and there are several known reports of unpleasant side effects experienced by some users.

Castor Oil May Help Relieve Arthritis, Sciatica and Back Pain

Story at-a-glance

  • Castor oil, derived from the castor seed, has been used for thousands of years to treat a wide variety of health conditions, although scientific studies are few; there are reports of some side negative effects from castor oil, so you should proceed with caution in experimenting with its use
  • Castor seeds contain very high concentrations of a special fatty acid called ricinoleic acid, thought to underlie its healing properties
  • Castor beans also contain a potent toxin called ricin—so deadly that it’s used for chemical warfare—but don’t worry, this agent is NOT present in the oil
  • Castor oil is claimed to treat gastrointestinal and genitourinary problems, all types of infections, and pain and inflammation, and is said to stimulate your immune system;science is also exploring the use of ricinas an antitumor agent
  • Advocates claim castor oil is most effective for strengthening your lymphatic system when it is applied topically in a “castor oil pack,” a treatment popularized by the late psychic healer Edgar Cayce

History of the Castor Seed: Ricinus Communis

Castor oil comes from the castor seed1, Ricinus communis, which has a very unusual chemical composition. Castor oil is a triglyceride, comprised of fatty acids, 90 percent of which is ricinoleic acid.

This unique fatty acid is found in lower concentrations in a few other seeds and oils (0.27 percent in cottonseed oil and 0.03 percent in soybean oil2) and is thought to be responsible for castor oil’s unique healing properties. The castor seed plant is native to India.

Centuries ago, the plant was referred to as “Palma Christe” because the leaves were said to resemble the hand of Christ. This association likely arose out of people’s reverence for the plant’s healing abilities.

It was later adopted for medicinal use in Ancient Egypt, China, Persia, Africa, Greece, Rome, and eventually in 17th Century Europe and the Americas. Castor oil is now widely used in industry. The stem of the plant is used in the textile industry, particularly in Russia, where castor oil is known as “Kastorka.”

The oil has a very consistent viscosity and won’t freeze, which makes it ideal for lubricating equipment in severely cold climates. Modern non-medicinal uses for castor oil include:

  • Food additive and flavoring agent
  • Mold inhibitor
  • Ingredient in skin care products and cosmetics (lipstick, shampoo, soap, and others)
  • Used in the manufacturing of plastics, rubbers, synthetic resins, fibers, paints, varnishes, lubricants, sealants, dyes, and leather treatments; the lubricants company Castrol took its name from castor oil

Castor oil was first used as an aircraft lubricant in World War I. So, castor oil has a number of handy industrial uses. But did you know that the castor seeds from which castor oil is made can be DEADLY?

Part of the Castor Seed Heals—But Another Part Kills!

The potent toxin ricin3 is made from a protein in the castor seeds that, if ingested (orally, nasally, or injected), gets into the ribosomes of your cells where it prevents protein synthesis, which kills the cells. Ricin is made from the “mash” that is left over after processing castor seeds into oil.

Just 1 milligram of ricin is fatal if inhaled or ingested, and much less than that if injected. Eating just 5 to 10 castor seeds would be fatal.

Once poisoned, there’s no antidote, which is why ricin has been used as a chemical warfare agent. Even though such a toxic component is also derived from this seed, castor oil isn’t considered dangerous.

According to the International Journal of Toxicology’s Final Report on Castor Oil4 , you don’t have to worry about castor oil being contaminated by ricin, because ricin does not “partition” into the castor oil. Castor oil has been added to cosmetic products for many years, without incident. For example, castor oil and hydrogenated castor oil were reportedly used in 769 and 202 cosmetic products, respectively, in 2002.

The U.S. FDA gives castor oil a “thumbs up,” deeming it “generally regarded as safe and effective” for use as a stimulant laxative.

The Joint Food and Agriculture Organization (FAO)/World Health Organization (WHO) Expert Committee on Food Additives has established an acceptable daily castor oil intake of up to 0.7 mg/kg body weight. This amounts to, roughly, one tablespoon for adults and one teaspoon for children. Taking castor oil orally usually results in a “purging” of the digestive tract in about four to six hours.

According to the International Castor Oil Association 5, castor oil studies in which people were dosed with castor oil at dietary concentrations as high as 10 percent for 90 days did not produce any ill effects.

In spite of the fact that U.S. FDA and the International Castor Oil Association have pronounced castor oil to be safe, if you are going to try it, as I’ve mentioned previously, proceed with extreme caution because a number of negative side effects have been reported.

Castor Oil is NOT without Side Effects

Castor Plant
Castor Seed Plant
http://faculty.ucc.edu/biology-ombrello/POW/castor_bean.htm

Castor oil’s main side effects fall into the categories of skin reactions and gastrointestinal upset, which isn’t terribly surprising given the agent’s actions on your intestinal wall.6

Castor oil is broken down by your small intestine into ricinoleic acid, which acts as an irritant to your intestinal lining.

This effect is what gives castor oil the ability to reverse constipation—but it’s also the reason that some people report digestive discomfort, diarrhea, and other gastrointestinal side effects.

If you suffer from cramps, irritable bowel, ulcers, diverticulitis, hemorrhoids, colitis, prolapses, or have recently undergone surgery, you should probably avoid castor oil due to these possible adverse reactions.

Although castor oil has been traditionally used to help stimulate labor in healthy pregnant women, there are widespread reports of nausea, including one study in 20017 that found nausea to be almost universally experienced by these women.

A Home Remedy that’s Survived for Millennia

Adverse effects notwithstanding, Indians would traditionally boil seed kernels or hulls in milk and water, and then consume the brew to relieve arthritis, lower back pain, and sciatica. According to Williams’ article8, castor seed plants are widely used in India for all sorts of medical problems, including the following:

  • Constipation
  • Dysentery
  • Inflammatory bowel disease
  • Bladder and vaginal infections
  • Asthma

Canary Islanders made poultices from the leaves of the castor plant to treat gynecological problems. Nursing mothers applied these poultices to their breasts to increase milk secretion and relieve inflammation of their mammary glands, and applied the poultice to their abdomens to promote normal menstruation. The topical absorption of castor oil is the basis for more modern “castor oil packs,” which I’ll be discussing later in detail.

Modern Medicinal Uses for Castor Oil

In general, the reported medicinal uses of castor oil fall into the following five general categories:

  1. Gastrointestinal remedy
  2. Antimicrobial (antibacterial, antiviral, and antifungal)
  3. Labor stimulant9
  4. Anti-inflammatory and analgesic
  5. Immune system and lymphatic stimulant

The oil’s benefits can be derived by topical application, and it appears to be useful for a variety of skin conditions like keratosis, dermatosis, wound healing, acne, ringworm, warts and other skin infections, sebaceous cysts, itching, and even hair loss. Castor oil and ricinoleic acid also enhance the absorption of other agents across your skin. And castor oil shows some promise in the treatment of cancer. According to the American Cancer Society10 :

“Oncologists now use castor oil as a vehicle for delivering some chemotherapy drugs to cancerous tumors. A special formula of castor oil called Cremophor EL is used as a carrier for paclitaxel, a drug used to treat metastatic breast cancer and other tumors. Unfortunately, the vehicle sometimes causes problems of its own, including allergic reactions. This has prompted a search for substitute carriers.”

They also report that early clinical trials suggest that ricin, when combined with an antibody to confine this poison to malignant cells, shrinks tumors in lymphoma patients. In fact, castor oil has been reportedly used to treat all of the following conditions listed below. While I certainly cannot attest to castor oil’s efficacy for all of these conditions (as there is not enough research to date), I list them here as a way to illustrate the wide array of possibilities.

Multiple sclerosis Parkinson’s Disease Cerebral Palsy
Arthritis Migraine and other headaches Cholecystitis (inflamed gallbladder)
Epilepsy Liver ailments, including cirrhosis Scleroderma
Appendicitis, colitis, and other intestinal problems AIDS Detoxification
Cancer Eye irritation Gynecological problems

Studies Support Castor Oil’s Efficacy as an Antimicrobial, Anti-Inflammatory, and Immunostimulant

While castor oil has been thoroughly investigated for its industrial use, only a minimal amount of research has been directed toward its medicinal benefits. That said, the healing properties of castor oil appear to have survived countless generations of scrutiny. I believe it has enough history behind it to at least warrant greater scientific exploration, and perhaps a little careful at-home experimentation on your own. Oftentimes, modern day scientific studies end up validating thousands of years of “folklore.” Castor oil studies are hard to track down, but I did find a few notable ones, which I have summarized in the table below.

Castor oil has been found to have a strong suppressive effect on some tumors.
An Indian study in 2011 found that castor leaf extract showed better antibacterial activity against both Gram-positive and Gram-negative bacteria than Gentamycin (their standard for comparison).11
A 2010 study found that castor oil packs were an effective means of decreasing constipation in the elderly.12
This 2009 study found that castor oil effectively relieves arthritis symptoms.13
A 1999 study14 was carried out to determine whether or not topical castor oil would stimulate the lymphatic system. The findings were positive. After a two-hour treatment with castor oil packs, there was a significant increase in the number of T-11 cells, which increased over a seven-hour period following treatment.
In this 2000 study15 of the effects of ricinoleic acid on inflammation, researchers found it exerted “capsaicin-like” antiinflammatory properties.
Patients with occupational dermatitis may have a positive reaction to castor oil or ricinoleic acid.16

Castor Oil May Promote Healing by Boosting Your Lymphatic System

One of the more compelling health benefits, if true, is castor oil’s support of your immune system. And this healing property does not require you ingest the oil, but only apply it externally.

The benefits of castor oil packs were popularized by the late psychic healer Edgar Cayce, and then later researched by primary care physician William McGarey of Phoenix, Arizona, a follower of Cayce’s work and the author of The Oil That Heals. McGarey reported that, when used properly, castor oil packs improve the function of your thymus gland and other components of your immune system. More specifically, he found in two separate studies that patients using abdominal castor oil packs had significant increases in lymphocyte production compared to placebo packs.

Lymphocytes are your immune system’s disease-fighting cells and are produced and stored mainly in your lymphatic tissue17 (thymus gland, spleen, and lymph nodes). Hundreds of miles of lymphatic tubules allow waste to be collected from your tissues and transported to your blood for elimination, a process referred to as lymphatic drainage. When your lymphatic system is not working properly, waste and toxins can build up and make you sick.

Lymphatic congestion is a major factor leading to inflammation and disease. This is where castor oil comes in. When castor oil is absorbed through your skin (according to Cayce and McGarey), your lymphocyte count increases. Increased lymphocytes speed up the removal of toxins from your tissues, which promotes healing.

Castor Oil Packs a Punch, Topically

Castor oil “packs” can be an economical and efficient method of infusing the ricinoleic acid and other healing components of castor oil directly into your tissues. You would be wise to do a “patch test” prior to applying a castor oil pack to make sure you aren’t allergic to the oil.

There are several ways to use castor oil topically. You can simply rub castor oil onto an affected area of your skin. Or, you can affix a Band-Aide soaked in castor oil if only a very small area needs to be treated. For larger or more systemic applications, it can be used as massage oil, which is reported especially effective when applied along your spinal column, massaged along your lymphatic drainage pathways. But the coup de grace of castor oil therapy is the “castor oil pack.” To make a castor oil pack, you will need the following supplies:

  1. High quality cold-pressed castor oil (see last section of this article)
  2. A hot water bottle or heating pad
  3. Plastic wrap, sheet of plastic, or plastic garbage bag
  4. Two or three one-foot square pieces of wool or cotton flannel, or one piece large enough to cover the entire treatment area when folded in thirds
  5. One large old bath towel

Below are instructions for making and using a castor oil pack (courtesy of Daniel H. Chong, ND):

  • Fold flannel three layers thick so it is still large enough to fit over your entire upper abdomen and liver, or stack the three squares.
  • Soak flannel with the oil so that it is completely saturated. The oil should be at room temperature.
  • Lie on your back with your feet elevated (using a pillow under your knees and feet works well), placing flannel pack directly onto your abdomen; cover oiled flannel with the sheet of plastic, and place the hot water bottle on top of the plastic.
  • Cover everything with the old towel to insulate the heat. Take caution not to get the oil on whatever you are laying on, as it can stain. If necessary, cover that surface with something to protect it.
  • Leave pack on for 45 to 60 minutes.
  • When finished, remove the oil from your skin by washing with a solution of two tablespoons of baking soda to one quart water, or just soap and water. (Be sure to wash the towel by itself, as the castor oil can make other clothes stink if washed together.)
  • You can reuse the pack several times, each time adding more oil as needed to keep the pack saturated. Store the pack in a large zip-lock bag or other plastic container in a convenient location, such as next to your bed. Replace the pack after it begins to change color.
  • For maximum effectiveness, apply at least four consecutive days per week for one month. Patients who use the pack daily report the most benefits.

Be Cautious When Purchasing Castor Oil

As with everything else, you must be careful about your source of castor oil. Much of the oil currently sold in stores is derived from castor seeds that have been heavily sprayed with pesticides, solvent-extracted (hexane is commonly used), deodorized, or otherwise chemically processed, which damages beneficial phytonutrients and may even contaminate the oil with toxic agents.

Again, let me emphasize, many of the health benefits of castor oil are more anecdotal than scientific, and side effects have been reported. As with anything new, proceed carefully so that you can minimize any unexpected reactions. I invite your comments about any experiences—positive or negative—related to your use of castor oil. I am always curious about your impressions and experience with natural remedies, and your feedback is welcome, as always.

Old Russian Remedy That Cures Inflammation, Arthritis And Rheumatism: Only One Application And You Will Never Feel Pain Again.


This old Russian remedy is made from few simple ingredients that you probably have in your home.

Recipe:

Ingredients:

  • 1 tablespoon of honey
  • 1 tablespoon of mustard (spicy)
  • 1 teaspoon of fine salt
  • 1 tablespoon of water

Preparation:

The preparation of this remedy is very simple. All you have to do is put all the ingredients into a bowl and mix them until you get a nice and smooth mixture. Then put this mixture in some container with a lid and store it in the refrigerator.

Application:

As for the application, you need to apply this mixture on the affected area. Then put a plastic bag over the affected area and finally wrap it with a cloth. Leave the remedy on for about 1.5 to 2 hours and then rinse the affected area with lukewarm water. For better results, you need to this procedure at night, right before going to bed. The results will follow immediately. However in order to get better results, you need to repeat this procedure for about 4 to in order to get better results, you need to repeat this procedure for about 4 to 5 days.

Note:

You should consult your doctor, before applying any natural remedies.

 

Scientists identify protein that will help treatment of arthritis .


Scientists have identified a protein that regulates the severity of tissue damage caused by rheumatoid arthritis.

Researchers have found that the protein, C5orf30, regulates the severity of tissue damage caused by rheumatoid arthritis (RA), an autoimmune disease that causes pain, inflammation, stiffness and damage to the joints of the feet, hips, knees, and hands.

Following the discovery, rheumatoid arthritis patients most likely to suffer the severest effects of the condition can now be identified early and fast-tracked to the more aggressive treatments available, researchers said.

Although there is no cure for RA, new effective drugs are increasingly available to treat the disease and prevent deformed joints.

To conduct the research, scientists from University College Dublin and the University of Sheffield, analyzed DNA samples and biopsy samples from joints of over 1,000 Rheumatoid arthritis patients in the UK and Ireland.

“Our findings provide a genetic marker that could be used to identify those RA patients who require more aggressive treatments or personalised medicine,” said Gerry Wilson from the University College Dublin’s School of Medicine and Medical Science in Ireland, who led the research.

“They also point to the possibility that increasing the levels of C5orf30 in the joints might be a novel method of reducing tissue damage caused by RA,” Wilson said.

“These exciting findings will prompt us to further explore the role of this highly conserved protein that we know so little about, and its significance in human health and disease,” said co-author Munitta Muthana from the University of Sheffield.

One of the biggest difficulties with treating rheumatoid arthritis is early diagnosis. With early diagnosis and aggressive treatment, it is possible to reduce the damage to the joints caused by RA.

Deciding the most appropriate treatment for each patient at the earliest possible stage is central to effectively tackling the condition, researchers said.

Scientists identify brain molecule that triggers schizophrenia-like behaviors, brain changes


Scientists at The Scripps Research Institute (TSRI) have identified a molecule in the brain that triggers schizophrenia-like behaviors, brain changes and global gene expression in an animal model. The research gives scientists new tools for someday preventing or treating psychiatric disorders such as schizophrenia, bipolar disorder and autism.

“This new model speaks to how schizophrenia could arise before birth and identifies possible novel drug targets,” said Jerold Chun, a professor and member of the Dorris Neuroscience Center at TSRI who was senior author of the new study.

The findings were published April 7, 2014, in the journal Translational Psychiatry.

What Causes Schizophrenia?

According to the World Health Organization, more than 21 million people worldwide suffer from schizophrenia, a severe psychiatric disorder that can cause delusions and hallucinations and lead to increased risk of suicide.

Although psychiatric disorders have a genetic component, it is known that environmental factors also contribute to disease risk. There is an especially strong link between psychiatric disorders and complications during gestation or birth, such as prenatal bleeding, low oxygen or malnutrition of the mother during pregnancy.

In the new study, the researchers studied one particular known risk factor: bleeding in the brain, called fetal cerebral hemorrhage, which can occur in utero and in premature babies and can be detected via ultrasound.

In particular, the researchers wanted to examine the role of a lipid called lysophosphatidic acid (LPA), which is produced during hemorrhaging. Previous studies had linked increased LPA signaling to alterations in architecture of the fetal brain and the initiation of hydrocephalus (an accumulation of brain fluid that distorts the brain). Both types of events can also increase the risk of psychiatric disorders.

“LPA may be the common factor,” said Beth Thomas, an associate professor at TSRI and co-author of the new study.

Mouse Models Show Symptoms

To test this theory, the research team designed an experiment to see if increased LPA signaling led to schizophrenia-like symptoms in animal models.

Hope Mirendil, an alumna of the TSRI graduate program and first author of the new study, spearheaded the effort to develop the first-ever animal model of fetal cerebral hemorrhage. In a clever experimental paradigm, fetal mice received an injection of a non-reactive saline solution, blood serum (which naturally contains LPA in addition to other molecules) or pure LPA.

The real litmus test to show if these symptoms were specific to psychiatric disorders, according to Mirendil, was “prepulse inhibition test,” which measures the “startle” response to loud noises. Most mice—and humans—startle when they hear a loud noise. However, if a softer noise (known as a prepulse) is played before the loud tone, mice and humans are “primed” and startle less at the second, louder noise. Yet mice and humans with symptoms of schizophrenia startle just as much at loud noises even with a prepulse, perhaps because they lack the ability to filter sensory information.

Indeed, the female mice injected with serum or LPA alone startled regardless of whether a prepulse was placed before the loud tone.

Next, the researchers analyzed brain changes, revealing schizophrenia-like changes in neurotransmitter-expressing cells. Global gene expression studies found that the LPA-treated mice shared many similar molecular markers as those found in humans with schizophrenia. To further test the role of LPA, the researchers used a molecule to block only LPA signaling in the brain.

This treatment prevented schizophrenia-like symptoms.

Implications for Human Health

This research provides new insights, but also new questions, into the developmental origins of psychiatric disorders.

For example, the researchers only saw symptoms in female mice. Could schizophrenia be triggered by different factors in men and women as well?

“Hopefully this animal model can be further explored to tease out potential differences in the pathological triggers that lead to disease symptoms in males versus females,” said Thomas.

In addition to Chun, Thomas and Mirendil, authors of the study, “LPA signaling initiates schizophrenia-like brain and behavioral changes in a mouse model of prenatal brain hemorrhage,” were Candy De Loera of TSRI; and Kinya Okada and Yuji Inomata of the Mitsubishi Tanabe Pharma Corporation.

Gene Linked With Pediatric Vasculitis


Spanish investigators have found an association between the human leukocyte antigen HLA-DRB1 gene locus and the childhood vasculitis Henoch-Schonlein purpura (HSP).

Genotyping of high-molecular- weight genomic DNA among a large cohort of patients with HSP revealed an increase in the HLA-DRB1*01 phenotype compared with a control group, with a frequency of 43% versus 27%, respectively, according to Miguel A. Gonzalez-Gay, MD, PhD, of Hospital Universitario Marques de Valdecilla in Santander, and colleagues.

The odds ratio for this phenotype therefore was 2.03 (95% CI 1.43-2.87, P<0.001), the researchers reported online in Arthritis and Rheumatology.

Henoch-Schonlein purpura, also known as immunoglobulin A vasculitis, is a small-vessel vasculitis characterized by palpable purpura of the lower extremities, as well as joint and gastrointestinal manifestations such as arthritis and bowel angina. Some patients also develop renal complications including hematuria and proteinuria, which can be persistent.

The cause of the disorder is unknown, although it’s thought that contributing factors include immunopathologic mechanisms and environmental influences. Familial clustering also has suggested that a genetic susceptibility may exist, as is the case with many other immune system disorders.

“The HLA region includes a group of genes located at chromosome 6 (6p21) that encodes the most polymorphic human proteins, the class I and class II antigen-presenting molecules. HLA is involved not only in the immune response against infectious pathogens, but also in the response against self-antigens,” Gonzalez-Gay and colleagues wrote.

It has been implicated in multiple immune and inflammatory diseases, “being associated with more diseases than any other region of the human genome,” they noted.

Among the conditions linked with variations in the HLA-DRB1 gene are rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis, as well as type 1 diabetes and multiple sclerosis.

Because earlier small studies also suggested a possible association with HSP, Gonzalez-Gay and colleagues conducted a genomic study of their large HSP cohort, which included 342 patients, along with 303 matched controls.

Patients’ mean age at the time of disease onset was 15 years, and duration of follow-up was 2.4 years. Slightly more than half of the patients were male.

All had the characteristic rash, 57% had arthritis or arthralgias, 54% had gastrointestinal manifestations, and 35% had renal involvement. In 7%, persistent renal sequelae were present.

The increase in the HLA-DRB1*01 phenotype seen among patients with HSP was primarily driven by a high rate of the HLA-DRB1*0103 allele, which was present in 14% of patients compared with only 2% of controls (OR 8.27, 95% CI 3.46-23.9, P<0.001).

In comparison, there was a decrease in frequency of the HLA-DRB1*03 phenotype, primarily because of the presence of the HLA-DRB1*0301 allele.

That allele was present in only 5.6% of patients but in 18.1% of controls (OR 0.26, 95% CI 0.14-0.47, P<0.001) and was considered to be protective. This possible protective effect needs to be confirmed in an independent cohort, the authors cautioned.

No differences were seen when patients were stratified according to joint, gastrointestinal, or renal manifestations.

HLA class II molecules have been linked with many other types of vasculitis, including giant cell arteritis, granulomatosis with polyangiitis, microscopic polyangiitis, and Kawasaki disease. The HLA-DRB1 locus has also been associated with the presence of mixed cryoglobulinemia in patients infected with hepatitis C.

“In conclusion, our study supports an association of HSP with HLA-DRB1. These results may have clinical implications as they may help to better identify patients with this vasculitis,” the researchers concluded.

Drug shows promise against arthritis common in people with psoriasis.


A new drug called brodalumab appears to be effective in treating patients suffering from psoriatic arthritis, a study says.

 

Patients who responded to brodalumab had a significant improvement in their skin and reduction in the swelling of the fingers and toes, a condition called dactylitis that is common in, according to the study’s lead researcher, Dr. Philip Mease, a rheumatologist at Swedish Medical Center in Seattle.

“We have a medication with a different mechanism of action than currently available drugs, increasing our chances to control this disease, which can be disabling and significantly affects‘ function and quality of life,” said Mease.

“We know that many patients will lose response to some medications or develop adverse effects, so there is a need for medicines that work differently,” he said. “We have a chance to bring patients back closer toward their normal state of being.”

The study was funded by Amgen, the maker of brodalumab. Results of the study were published June 12 in the New England Journal of Medicine. The study’s findings were also scheduled to be presented on Thursday at the European Congress of Rheumatology’s annual meeting in Paris.

Psoriatic  is a type of arthritic inflammation that affects as many as 30 percent of people who have psoriasis, according to background information in the study.

Psoriasis causes scaly red and white patches on the skin, according to the American College of Rheumatology (ACR). In psoriatic arthritis, the immune system attacks the joints as well, causing inflammation. Persistent inflammation from psoriatic arthritis can lead to joint damage, according to the ACR.

Like psoriasis, psoriatic arthritis symptoms come and go, vary from person to person, and even change locations over time.

Psoriatic arthritis may affect one joint or several. For example, it may affect one or both knees. Affected fingers and toes can become swollen. Fingernails and toenails also may be affected.

Mease noted that psoriatic arthritis has a genetic component that makes it distinct from other types of arthritis.

“There are also certain genes that are present in people who develop the arthritis that are not present in people with psoriasis. So there seems to be a heavy genetic component for determining who gets psoriasis and goes on to get psoriatic arthritis,” he said.

Current treatment for psoriatic arthritis depends on how much pain the patient has. Treatment usually starts with painkillers such as ibuprofen (Motrin or Advil) or naproxen (Aleve).

Mease noted that many patients are also given methotrexate (Trexall), which treats both arthritis and psoriasis. Other drugs, known as biologic therapy, that are also used to treat both conditions include adalimumab (Humira), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade).

Current drugs such as methotrexate target a substance called tumor necrosis factor-alpha, which is produced in response to inflammation. But these drugs tend to be less effective over time, Mease said.

Brodalumab works differently. It acts against interleukin-17 receptor A, a substance found in higher levels in people with psoriatic arthritis, according to the study.

For the current phase 2 trial of brodalumab, Mease and colleagues randomly assigned 168 patients with psoriatic arthritis to a low (140 milligrams) or high dose (280 milligrams) of brodalumab, or a placebo.

The average age of the study participant was 52 years. Two-thirds of the study volunteers were women and 94 percent were white (which included Hispanics and Latinos). The average amount of time they’d had psoriatic arthritis was nine years, according to the study.
After 12 weeks, patients taking either dose of brodalumab had a greater response to treatment than those receiving placebo (37 percent and 39 percent versus 18 percent).

Moreover, 14 percent of those taking brodalumab had a 50 percent improvement in symptoms based on the American College of Rheumatology response criteria, compared with 4 percent who received the placebo, the researchers found.

Improvements were seen in both patients who had previous biologic therapy, as well as those who had not had biologic therapy in the past, the researchers noted.

After 24 weeks of treatment, 51 percent of patients taking the lower dose of brodalumab and 64 percent taking the higher dose responded to the drug. In addition, 44 percent of the patients who switched from placebo to brodalumab responded to treatment.

These responses were maintained through a year, the researchers said.

At week 12, serious side effects occurred in 3 percent of patients in the brodalumab groups and in 2 percent of those in the placebo group, they add. These included stomach pain and a skin infection called cellulitis. “This is consistent with what had been seen with other so-called biologic medications,” Mease said.

Dr. Robert Kirsner is a professor and vice chairman of the department of dermatology and cutaneous surgery at the University of Miami Miller School of Medicine. “The results of this, albeit small study are extremely encouraging for patients who suffer from these conditions and for the physicians who treat them,” Kirsner, who was not part of the study, said.

A phase 3 trial—the last step before potential U.S. Food and Drug Administration approval—is under way, testing brodalumab as a treatment for psoriasis. According to Mease, Amgen hopes to have the drug approved for  first, and then as a treatment for psoriatic arthritis.

Rheumatoid Arthritis: Painful Debilitating Disease More Devastating Than Previously Recognized.


Story at-a-glance

  • A revised and updated drug-free RA protocol based on a pioneering rheumatoid arthritis treatment tends to provide a 60-90 percent improvement rate in most RA sufferers
  • Important aspects of the treatment protocol include dietary modifications, low-dose Naltrexone, optimizing your vitamin D levels, astaxanthin, probiotics (preferably in the form of fermented foods), and getting regular exercise
  • Pain control is an important aspect of treating RA. Ideally, you’ll want to use the safest drugs and only when necessary, with the ultimate goal of managing your pain without medications. Some of the safest prescription drugs for pain are the non-acetylated salicylates, such as salsalate, sodium salicylate, and magnesium salicylate (i.e. Salflex, Disalcid, or Trilisate).
  • Rheumatoid arthritis affects about one percent of our population and at least two million Americans have definite or classical rheumatoid arthritis. This number has increased in recent years, as in 2010 about 2.5 percent of white women developed RA.

    It is a much more devastating illness than previously appreciated. Most patients with rheumatoid arthritis have a progressive disability.

    The natural course of rheumatoid arthritis is quite remarkable in that less than one percent of people with the disease have a spontaneous remission. Some disability occurs in 50-70 percent of people within five years after onset of the disease, and half will stop working within 10 years. The annual cost of this disease in the U.S. is estimated to be over $1 billion.

    This devastating prognosis is what makes this novel form of treatment so exciting, as it has a far higher likelihood of succeeding than the conventional approach.

    Over the years I have treated over 3,000 patients with rheumatic illnesses, including SLE, scleroderma, polymyositis and dermatomyositis.

    Approximately 15 percent of these patients were lost to follow-up for whatever reason and have not continued with treatment. The remaining patients seem to have a 60-90 percent likelihood of improvement on this treatment regimen.

    This level of improvement is quite a stark contrast to the typical numbers quoted above that are experienced with conventional approaches, and certainly a strong motivation to try the protocol I discuss below.

    Rheumatoid Arthritis Can Be Deadlier Than Heart Disease

    There is also an increased mortality rate with this disease. The five-year survival rate of patients with more than 30 joints involved is approximately 50 percent. This is similar to severe coronary artery disease or stage IV Hodgkin’s disease.

    Thirty years ago, one researcher concluded that there was an average loss of 18 years of life in patients who developed rheumatoid arthritis before the age of 50.

    Most authorities believe that remissions rarely occur. Some experts feel that the term “remission-inducing” should not be used to describe ANY current rheumatoid arthritis treatment, and a review of contemporary treatment methods shows that medical science has not been able to significantly improve the long-term outcome of this disease.

    Dr. Brown Pioneered a Novel Approach to Treat Rheumatoid Arthritis

    I first became aware of Doctor Brown’s protocol in 1989 when I saw him on 20/20 on ABC. This was shortly after the introduction of the first edition of his book, The Road Back.

    Unfortunately, Dr. Brown died from prostate cancer shortly after the 20/20 program, so I never had a chance to meet him.

    My application of Dr. Brown’s protocol has changed significantly since I first started implementing it. Initially, I rigidly followed Dr. Brown’s work with minimal modifications to his protocol.

    About the only change I made was changing Tetracycline to Minocin. I believe I was one of the first physicians who recommended the shift to Minocin, and most people who use his protocol now use Minocin.

    In 1939, Dr. Sabin, the discoverer of the polio vaccine, first reported chronic arthritis in mice caused by a mycoplasma. He suggested this agent might cause human rheumatoid arthritis. Dr. Brown worked with Dr. Sabin at the Rockefeller Institute.

    Dr. Brown was a board certified rheumatologist who graduated from Johns Hopkins medical school. He was a professor of medicine at George Washington University until 1970 where he served as chairman of the Arthritis Institute in Arlington, Virginia. He published over 100 papers in peer reviewed scientific literatureHe was able to help over 10,000 patients when he used this program, from the 1950s until his death in 1989, and clearly far more than that have been helped by other physicians using this protocol.

    He found that significant benefits from the treatment require, on average, about one to two years.

    I have treated nearly 3000 patients and find that the dietary modification I advocate, which I started to integrate in the early 1990s, accelerates the response rate to several months. I cannot emphasize strongly enough the importance of this aspect of the program.

    Still, the length of therapy can vary widely.

    In severe cases, it may take up to 30 months for patients to gain sustained improvement. One requires patience because remissions may take up to three to five years. Dr. Brown’s pioneering approach represents a safer, less toxic alternative to many conventional regimens and results of the NIH trial have finally scientifically validated this treatment.

    The dietary changes are absolutely an essential component of my protocol. Dr. Brown’s original protocol was notorious for inducing a Herxheimer, or worsening of symptoms, before improvement was noted. This could last two to six months. Implementing my nutrition plan resulted in a lessening of that reaction in most cases.

    When I first started using his protocol for patients in the late ’80s, the common retort from other physicians was that there was “no scientific proof” that this treatment worked. Well, that is certainly not true today. A review of the bibliography will provide over 200 references in the peer-reviewed medical literature that supports the application of Minocin in the use of rheumatic illnesses.

    In my experience, nearly 80 percent of people do remarkably better with this program. However, approximately five percent continue to worsen and require conventional agents, like methotrexate, to relieve their symptoms.

    Scientific Proof for This Approach

    The definitive scientific support for minocycline in the treatment of rheumatoid arthritis came with the MIRA trial in the United States. This was a double blind randomized placebo controlled trial done at six university centers involving 200 patients for nearly one year. The dosage they used (100 mg twice daily) was much higher and likely less effective than what most clinicians currently use.

    They also did not employ any additional antibiotics or nutritional regimens, yet 55 percent of patients improved. This study finally provided the “proof” that many traditional clinicians demanded before seriously considering this treatment as an alternative regimen for rheumatoid arthritis.

    Dr. Thomas Brown’s effort to treat the chronic mycoplasma infections believed to cause rheumatoid arthritis is the basis for this therapy. Dr. Brown believed that most rheumatic illnesses respond to this treatment. He and others used this therapy for SLE, ankylosing spondylitis, scleroderma, dermatomyositis, and polymyositis.

    Dr. Osler was one of the most well respected and prominent physicians of his time (1849- 1919), and many regard him as the consummate physician of modern times. An excerpt from a commentary on Dr. William Osler provides a useful perspective on application of alternative medical paradigms:

    Osler would caution us against the arrogance of believing that only our current medical practices can benefit the patient. He would realize that new scientific insights might emerge from as yet unproved beliefs. Although he would fight vigorously to protect the public against frauds and charlatans, he would encourage critical study of whatever therapeutic approaches were reliably reported to be beneficial to patients.

    Factors Associated with Your Success on This Program

    There are many variables associated with an increased chance of remission or improvement.

    • The younger you are, the greater your chance for improvement
    • The more closely you follow the nutrition plan, the more likely you are to improve and the less likely you are to have a severe flare-up. I now offer the Nutritional Typing Test for free, so please do not skip this essential step.
    • Smoking seems to be negatively associated with improvement
    • The longer you have had the illness and the more severe the illness, the more difficult it seems to treat

    Revised Antibiotic-Free Approach

    Although I used a revision of his antibiotic approach for nearly 10 years, my particular prejudice is to focus on natural therapies. The program that follows is my revision of this protocol that allows for a completely drug-free treatment of RA, which is based on my experience of treating over 3000 patients with rheumatic illnesses in my Chicago clinic.

    If you are interested in reviewing or considering Dr. Brown’s antibiotic approach, I have included a summary of his work and the evidence for it in the appendix.

    Crucial Lifestyle Changes

    Improving your diet using a combination of my nutritional guidelines, nutritional typing is crucial for your success. In addition, there are some general principles that seem to hold true for all nutritional types and these include:

    • Eliminating sugar, especially fructose, and most grains. For most people it would be best to limit fruit to small quantities
    • Eating unprocessed, high-quality foods, organic and locally grown if possible
    • Eating your food as close to raw as possible
    • Getting plenty high-quality, animal-based omega-3 fats. Krill oil seems to be particularly helpful here as it appears to be a more effective anti inflammatory preparation. It is particularly effective if taken concurrently with 4 mg of Astaxanthin, which is a potent antioxidant bioflavanoid derived from algae
    • Astaxanthin at 4 mg per day is particularly important for anyone placed on prednisone as Astaxanthin offers potent protection against cataracts and age related macular degeneration
    • Incorporating regular exercise into your daily schedule

    Early Emotional Traumas Are Pervasive in Those with Rheumatoid Arthritis

    With the vast majority of the patients I treated, some type of emotional trauma occurred early in their life, before the age their conscious mind was formed, which is typically around the age of 5 or 6. However, a trauma can occur at any age, and has a profoundly negative impact.

    If that specific emotional insult is not addressed with an effective treatment modality then the underlying emotional trigger will continue to fester, allowing the destructive process to proceed, which can predispose you to severe autoimmune diseases like RA later in life.

    In some cases, RA appears to be caused by an infection, and it is my experience that this infection is usually acquired when you have a stressful event that causes a disruption in your bioelectrical circuits, which then impairs your immune system.

    This early emotional trauma predisposes you to developing the initial infection, and also contributes to your relative inability to effectively defeat the infection.

    Therefore, it’s very important to have an effective tool to address these underlying emotional traumas. In my practice, the most common form of treatment used is called the Emotional Freedom Technique (EFT).

    Although EFT is something that you can learn to do yourself in the comfort of your own home, it is important to consult a well-trained professional to obtain the skills necessary to promote proper healing using this amazing tool.

    Vitamin D Deficiency Rampant in Those with Rheumatoid Arthritis

    The early part of the 21st century brought enormous attention to the importance and value of vitamin D, particularly in the treatment of autoimmune diseases like RA.

    From my perspective, it is now virtually criminal negligent malpractice to treat a person with RA and not aggressively monitor their vitamin D levels to confirm that they are in a therapeutic range of 65-80 ng/ml.

    This is so important that blood tests need to be done every two weeks, so the dose can be adjusted to get into that range. Most normal-weight adults should start at 10,000 units of vitamin D per day.

    If you are in the US, then Lab Corp is the lab of choice.

    For more detailed information on vitamin D, you can review my vitamin D resource page.

    Low-Dose Naltrexone

    One new addition to the protocol is low-dose Naltrexone, which I would encourage anyone with RA to try. It is inexpensive and non-toxic and I have a number of physician reports documenting incredible efficacy in getting people off of all their dangerous arthritis meds.

    Although this is a drug, and strictly speaking not a natural therapy, it has provided important relief and is FAR safer than the toxic drugs that are typically used by nearly all rheumatologists.

    Nutritional Considerations

    Limiting sugar is a critical element of the treatment program. Sugar has multiple significant negative influences on your biochemistry. First and foremost, it increases your insulin levels, which is the root cause of nearly all chronic disease. It can also impair your gut bacteria.

    In my experience if you are unable to decrease your sugar intake, you are far less likely to improve. Please understand that the number one source of calories in the US is high fructose corn syrup from drinking soda. One of the first steps you can take is to phase out all soda, and replace it with pure, clean water.

    Exercise for Rheumatoid Arthritis

    It is very important to exercise and increase muscle tone of your non-weight bearing joints. Experts tell us that disuse results in muscle atrophy and weakness. Additionally, immobility may result in joint contractures and loss of range of motion (ROM). Active ROM exercises are preferred to passive.

    There is some evidence that passive ROM exercises increase the number of white blood cells (WBCs) in your joints.

    If your joints are stiff, you should stretch and apply heat before exercising. If your joints are swollen, application of 10 minutes of ice before exercise would be helpful.

    The inflamed joint is very vulnerable to damage from improper exercise, so you must be cautious. People with arthritis must strike a delicate balance between rest and activity, and must avoid activities that aggravate joint pain. You should avoid any exercise that strains a significantly unstable joint.

    A good rule of thumb is that if the pain lasts longer than one hour after stopping exercise, you should slow down or choose another form of exercise. Assistive devices are also helpful1 to decrease the pressure on affected joints. Many patients need to be urged to take advantage of these. The Arthritis Foundation has a book, Guide to Independent Living, which instructs patients about how to obtain them.

    Of course, it is important to maintain good cardiovascular fitness as well. Walking with appropriate supportive shoes is another important consideration.

    If your condition allows, it would be wise to move toward a Peak Fitness program that is designed for reaching optimal health.

    It’s Important to Control Your Pain

    One of the primary problems with RA is controlling pain. The conventional treatment typically includes using very dangerous drugs like prednisone, methotrexate, and drugs that interfere with tumor necrosis factor, like Enbrel.

    The goal is to implement the lifestyle changes discussed above as quickly as possible, so you can start to reduce these toxic and dangerous drugs, which do absolutely nothing to treat the cause of the disease.

    However, pain relief is obviously very important, and if this is not achieved, you can go into a depressive cycle that can clearly worsen your immune system and cause the RA to flare.

    So the goal is to be as comfortable and pain free as possible with the least amount of drugs. The Mayo Clinic offers several common sense guidelines2 for avoiding pain by paying heed to how you move, so as to not injure your joints.

    Safest Anti-Inflammatories to Use for Pain

    Clearly the safest prescription drugs to use for pain are the non-acetylated salicylates such as:

    • Salsalate
    • Sodium salicylate
    • Magnesium salicylate (i.e., Salflex, Disalcid, or Trilisate)

    They are the drugs of choice if there is renal insufficiency, as they minimally interfere with anticyclooxygenase and other prostaglandins.

    Additionally, they will not impair platelet inhibition in those patients who are on an every-other-day aspirin regimen to decrease their risk for stroke or heart disease.

    Unlike aspirin, they do not increase the formation of products of lipoxygenase-mediated metabolism of arachidonic acid. For this reason, they may be less likely to cause hypersensitivity reactions. These drugs have been safely used in patients with reversible obstructive airway disease and a history of aspirin sensitivity.

    They are also much gentler on your stomach than the other NSAIDs and are the drug of choice if you have problems with peptic ulcer disease. Unfortunately, all these benefits are balanced by the fact that they may not be as effective as the other agents and are less convenient to take. You need to take 1.5-2 grams twice a day, and tinnitus, or ringing in your ear, is a frequent side effect.

    You need to be aware of this complication and know that if tinnitus does develop, you need to stop the drugs for a day and restart with a dose that is half a pill per day lower. You can repeat this until you find a dose that relieves your pain and doesn’t cause any ringing in your ears.

    If the Safer Anti-Inflammatories Aren’t Helping, Try This Next…

    If the non-acetylated salicylates aren’t helping, there are many different NSAIDs to try. Relafen, Daypro, Voltaren, Motrin, Naprosyn. Meclomen, Indocin, Orudis, and Tolectin are among the most toxic or likely to cause complications. You can experiment with them, and see which one works best for you.

    If cost is a concern, generic ibuprofen can be used at up to 800 mg per dose. Unfortunately, recent studies suggest this drug is more damaging to your kidneys.

    If you use any of the above drugs, though, it is really important to make sure you take them with your largest meal as this will somewhat moderate their GI toxicity and the likelihood of causing an ulcer.

    Please beware that they are much more dangerous than the antibiotics or non-acetylated salicylates.

    You should have an SMA blood test performed at least once a year if you are on these medications. In addition, you must monitor your serum potassium levels if you are on an ACE inhibitor as these medications can cause high potassium levels. You should also monitor your kidney function. The SMA will show any liver impairment the drugs might be causing.

    These medications can also impair prostaglandin metabolism and cause papillary necrosis and chronic interstitial nephritis. Your kidney needs vasodilatory prostaglandins (PGE2 and prostacyclin) to counterbalance the effects of potent vasoconstrictor hormones such as angiotensin II and catecholamines. NSAIDs decrease prostaglandin synthesis by inhibiting cyclooxygenase, leading to unopposed constriction of the renal arterioles supplying your kidney.

    Warning: These Drugs Massively Increase Your Risk for Ulcers

    The first non-aspirin NSAID, indomethacin, was introduced in 1963. Now more than 30 are available. Relafen is one of the better alternatives as it seems to cause less of an intestinal dysbiosis.

    You must be especially careful to monitor renal function periodically. It is important to understand and accept the risks associated with these more toxic drugs.

    Every year, they do enough damage to the GI tract to kill 2,000 to 4,000 people with rheumatoid arthritis alone. That is 10 people EVERY DAY. At any given time, 10 to 20 percent of all those receiving NSAID therapy have gastric ulcers.

    If you are taking an NSAID, you are at approximately three times greater risk for developing serious gastrointestinal side effects than those who don’t.

    Approximately 1.2 percent of patients taking NSAIDs are hospitalized for upper GI problems, per year of exposure. One study of patients taking NSAIDs showed that a life-threatening complication was the first sign of ulcer in more than half of the subjects.

    Researchers found that the drugs suppress production of prostacyclin, which is needed to dilate blood vessels and inhibit clotting. Earlier studies had found that mice genetically engineered to be unable to use prostacyclin properly were prone to clotting disorders.

    Anyone who is at increased risk of cardiovascular disease should steer clear of these medications. Ulcer complications are certainly potentially life-threatening, but heart attacks are a much more common and likely risk, especially in older individuals.

    How You Can Tell if You Are at Risk for NSAID Side Effects

    Risk factor analysis can help determine if you will face an increased danger of developing these complications. If you have any of the following, you will likely to have a higher risk of side effects from these drugs:

    1. Old age
    2. Peptic ulcer history
    3. Alcohol dependency
    4. Cigarette smoking
    5. Concurrent prednisone or corticosteroid use
    6. Disability
    7. Taking a high dose of the NSAID
    8. Using an NSAID known to be more toxic

    Prednisone

    The above drug class are called non steroidal anti inflammatories (NSAIDs). If they are unable to control the pain, then prednisone is nearly universally used. This is a steroid drug that is loaded with side effects.

    If you are on large doses of prednisone for extended periods of time, you can be virtually assured that you will develop the following problems:

    • Osteoporosis
    • Cataracts
    • Diabetes
    • Ulcers
    • Herpes reactivation
    • Insomnia
    • Hypertension
    • Kidney stones

    You can be virtually assured that every time you take a dose of prednisone your bones are becoming weaker. The higher the dose and the longer you are on prednisone, the more likely you are to develop the problems.

    However, if you are able to keep your dose to 5 mg or below, this is not typically a major issue.

    Typically this is one of the first medicines you should try to stop as soon as your symptoms permit.

    Beware that blood levels of cortisol peak between 3 and 9am. It would, therefore, be safest to administer the prednisone in the morning. This will minimize the suppression on your hypothalamic-pituitary-adrenal axis.

    You also need to be concerned about the increased risk of peptic ulcer disease when using this medicine with conventional non-steroidal anti-inflammatories. If you are taking both of these medicines, you have a 15 times greater risk of developing an ulcer!

    If you are already on prednisone, it is helpful to get a prescription for 1 mg tablets so you can wean yourself off the prednisone as soon as possible. Usually you can lower your dose by about 1 mg per week. If a relapse of your symptoms occurs, then further reduction of the prednisone is not indicated.

    How Do You Know When to Stop the Drugs?

    Unlike conventional approaches to RA, my protocol is designed to treat the underlying cause of the problem. So eventually the drugs that you are going to use during the program will be weaned off.

    The following criteria can help determine when you are in remission and can consider weaning off your medications:

    • A decrease in duration of morning stiffness to no more than 15 minutes
    • No pain at rest
    • Little or no pain or tenderness on motion
    • Absence of joint swelling
    • A normal energy level
    • A decrease in your ESR to no more than 30
    • A normalization of your CBC. Generally your HGB, HCT, & MCV will increase to normal and your “pseudo”-iron deficiency will disappear
    • ANA, RF, & ASO titers returning to normal

    If you discontinue your medications before all of the above criteria are met, there is a greater risk that the disease will recur.

    If you meet the above criteria, you can try to wean off your anti-inflammatory medication and monitor for flare-ups. If no flare-ups occur for six months, then discontinue the clindamycin.

    If the improvements are maintained for the next six months, you can then discontinue your Minocin and monitor for recurrences. If symptoms should recur, it would be wise to restart the previous antibiotic regimen.

    Evaluation to Determine and Follow Rheumatoid Arthritis

    If you have received evaluations and treatment by one or more board certified rheumatologists, you can be very confident that the appropriate evaluation was done. Although conventional treatments fail miserably in the long run, the conventional diagnostic approach is typically excellent, and you can start the treatment program discussed above.

    If you have not been evaluated by a specialist then it will be important to be properly evaluated to determine if indeed you have rheumatoid arthritis.

    Please be sure and carefully review Appendix Two, as you will want to confirm that fibromyalgia is not present.

    Beware that arthritic pain can be an early manifestation of 20-30 different clinical problems.

    These include not only rheumatic disease, but also metabolic, infectious and malignant disorders. Rheumatoid arthritis is a clinical diagnosis for which there is not a single test or group of laboratory tests that can be considered confirmatory.

    Criteria for Classification of Rheumatoid Arthritis

    • Morning Stiffness – Morning stiffness in and around joints lasting at least one hour before maximal improvement is noted.
    • Arthritis of three or more joint areas – At least three joint areas have simultaneously had soft-tissue swelling or fluid (not bony overgrowth) observed by a physician. There are 14 possible joints: right or left PIP, MCP, wrist, elbow, knee, ankle, and MTP joints.
    • Arthritis of hand joints – At least one joint area swollen as above in a wrist, MCP, or PIP joint.
    • Symmetric arthritis – Simultaneous involvement of the same joint areas (as in criterion 2) on both sides of your body (bilateral involvement of PIPs, MCPs, or MTPs) is acceptable without absolute symmetry. Lack of symmetry is not sufficient to rule out the diagnosis of rheumatoid arthritis.
    • Rheumatoid Nodules – Subcutaneous nodules over bony prominences, or extensor surfaces, or in juxta-articular regions, observed by a physician. Only about 25 percent of patients with rheumatoid arthritis develop nodules, and usually as a later manifestation.
    • Serum Rheumatoid Factor – Demonstration of abnormal amounts of serum rheumatoid factor by any method that has been positive in less than 5 percent of normal control subjects. This test is positive only 30-40 percent of the time in the early months of rheumatoid arthritis.

    You must also make certain that the first four symptoms listed in the table above are present for six or more weeks. These criteria have a 91-94 percent sensitivity and 89 percent specificity for the diagnosis of rheumatoid arthritis.

    However, these criteria were designed for classification and not for diagnosis. The diagnosis must be made on clinical grounds. It is important to note that many patients with negative serologic tests can have a strong clinical picture for rheumatoid arthritis.

    Your Hands Are the KEY to the Diagnosis of Rheumatoid Arthritis

    In a way, the hands are the calling card of rheumatoid arthritis. If you completely lack hand and wrist involvement, even by history, the diagnosis of rheumatoid arthritis is doubtful. Rheumatoid arthritis rarely affects your hips and ankles early in its course.

    The metacarpophalangeal joints, proximal interphalangeal and wrist joints are the first joints to become symptomatic. Osteoarthritis typically affects the joints that are closest to your fingertips (DIP joints) while RA typically affects the joints closest to your wrist (PIP), like your knuckles.

    Fatigue may be present before your joint symptoms begin, and morning stiffness is a sensitive indicator of rheumatoid arthritis. An increase in fluid in and around your joint probably causes the stiffness. Your joints are warm, but your skin is rarely red.

    When your joints develop effusions, hold them flexed at 5 to 20 degrees as it is likely going to be too painful to extend them fully.

    Radiological Changes

    Radiological changes typical of rheumatoid arthritis on PA hand and wrist X-rays, which must include erosions or unequivocal bony decalcification localized to, or most marked, adjacent to the involved joints (osteoarthritic changes alone do not count).

    Note: You must satisfy at least four of the seven criteria listed. Any of criteria 1-4 must have been present for at least 6 weeks. Patients with two clinical diagnoses are not excluded. Designations as classic, definite, or probable rheumatoid arthritis, are not to be made.

    Laboratory Evaluation

    The general initial laboratory evaluation should include a baseline ESR, CBC, SMA, U/A, 25 hydroxy D level and an ASO titer. You can also draw RF and ANA titers to further objectively document improvement with the therapy. However, they seldom add much to the assessment.

    Follow-up visits can be every two to four months depending on the extent of the disease and ease of testing.

    The exception here would be vitamin D testing, which should be done every two weeks until your 25 hydroxy D level is between 65 and 80 ng/ml.

    Many patients with rheumatoid arthritis have a hypochromic, microcytic CBC that appears very similar to iron deficiency, but it is not at all related. This is probably due to the inflammation in the rheumatoid arthritis impairing optimal bone marrow utilization of iron.

    It is important to note that this type of anemia does NOT respond to iron and if you are put on iron you will get worse, as the iron is a very potent oxidative stress. Ferritin levels are generally the most reliable indicator of total iron body stores. Unfortunately it is also an acute phase reactant protein and will be elevated anytime the ESR is elevated. This makes ferritin an unreliable test in patients with rheumatoid arthritis.

    Physicians Who Use This Protocol

    Roadback.org is the oldest organization promoting this work and the one Dr. Brown originally worked with.  They are an excellent resource to find health care professionals using this approach.

    APPENDIX ONE: The Infectious Cause of Rheumatoid Arthritis

    It is quite clear that autoimmunity plays a major role in the progression of rheumatoid arthritis. Most rheumatology investigators believe that an infectious agent causes rheumatoid arthritis. There is little agreement as to the involved organism, however.

    Investigators have proposed the following infectious agents:

    • Human T-cell lymphotropic virus Type I
    • Rubella virus
    • Cytomegalovirus
    • Herpesvirus
    • Mycoplasma

    This review will focus on the evidence supporting the hypothesis that mycoplasma is a common etiologic agent of rheumatoid arthritis.

    Mycoplasmas are the smallest self-replicating prokaryotes. They differ from classical bacteria by lacking rigid cell wall structures and are the smallest known organisms capable of extracellular existence. They are considered parasites of humans, animals, and plants.

    Culturing Mycoplasmas from Joints

    Mycoplasmas have limited biosynthetic capabilities and are very difficult to culture and grow from synovial tissues. They require complex growth media or a close parasitic relation with animal cells. This contributed to many investigators’ failure to isolate them from arthritic tissue.

    In reactive arthritis, immune complexes rather than viable organisms localize in your joints. The infectious agent is actually present at another site. Some investigators believe that the organism binding in the immune complex contributes to the difficulty in obtaining positive mycoplasma cultures.

    Despite this difficulty, some researchers have successfully isolated mycoplasma from synovial tissues of patients with rheumatoid arthritis. A British group used a leucocyte-migration inhibition test and found two-thirds of their rheumatoid arthritis patients to be infected with Mycoplasma fermentens. These results are impressive since they did not include more prevalent Mycoplasma strains like M salivarium, M ovale, M hominis, and M pneumonia.

    One Finnish investigator reported a 100 percent incidence of isolation of mycoplasma from 27 rheumatoid synovia using a modified culture technique. None of the non-rheumatoid tissue yielded any mycoplasmas.

    The same investigator used an indirect hemagglutination technique and reported mycoplasma antibodies in 53 percent of patients with definite rheumatoid arthritis. Using similar techniques, other investigators have cultured mycoplasma in 80-100 percent of their rheumatoid arthritis test population.

    Rheumatoid arthritis can also follow some mycoplasma respiratory infections.

    One study of over 1,000 patients was able to identify arthritis in nearly one percent of the patients. These infections can be associated with a positive rheumatoid factor. This provides additional support for mycoplasma as an etiologic agent for rheumatoid arthritis. Human genital mycoplasma infections have also caused septic arthritis.

    Harvard investigators were able to culture mycoplasma or a similar organism, ureaplasma urealyticum, from 63 percent of female patients with SLE and only four percent of patients with CFS. The researchers chose CFS, as these patients shared similar symptoms as those with SLE, such as fatigue, arthralgias, and myalgias.

    Animal Evidence for the Protocol

    The full spectrum of human rheumatoid arthritis immune responses (lymphokine production, altered lymphocyte reactivity, immune complex deposition, cell-mediated immunity, and development of autoimmune reactions) occurs in mycoplasma induced animal arthritis

    Investigators have implicated at least 31 different mycoplasma species.

    Mycoplasma can produce experimental arthritis in animals from three days to months later. The time seems to depend on the dose given, and the virulence of the organism.

    There is a close degree of similarity between these infections and those of human rheumatoid arthritis.

    Mycoplasmas cause arthritis in animals by several mechanisms. They either directly multiply within the joint or initiate an intense local immune response.

    Arthritogenic mycoplasmas also cause joint inflammation in animals by several mechanisms. They induce nonspecific lymphocyte cytotoxicity and antilymphocyte antibodies as well as rheumatoid factor.

    Mycoplasma clearly causes chronic arthritis in mice, rats, fowl, swine, sheep, goats, cattle, and rabbits. The arthritis appears to be the direct result of joint infection with culturable mycoplasma organisms.

    Gorillas have tissue reactions closer to man than any other animal, and investigators have shown that mycoplasma can precipitate a rheumatic illness in gorillas. One study demonstrated that mycoplasma antigens do occur in immune complexes in great apes.

    The human and gorilla IgG are very similar and express nearly identical rheumatoid factors (IgM anti-IgG antibodies). The study showed that when mycoplasma binds to IgG it can cause a conformational change. This conformational change results in an anti-IgG antibody, which can then stimulate an autoimmune response.

    The Science of Why Minocycline Is Used

    If mycoplasma were a causative factor in rheumatoid arthritis, one would expect tetracycline type drugs to provide some sort of improvement in the disease. Collagenase activity increases in rheumatoid arthritis and probably has a role in its cause.

    Investigators have demonstrated that tetracycline and minocycline inhibit leukocyte, macrophage, and synovial collagenase.

    There are several other aspects of tetracyclines that may play a role in rheumatoid arthritis. Investigators have shown minocycline and tetracycline to retard excessive connective tissue breakdown and bone resorption, while doxycycline inhibits digestion of human cartilage.

    It is also possible that tetracycline treatment improves rheumatic illness by reducing delayed-type hypersensitivity response. Minocycline and doxycycline both inhibit phosolipases, which are considered proinflammatory and capable of inducing synovitis.

    Minocycline is a more potent antibiotic than tetracycline and penetrates tissues better.

    These characteristics shifted the treatment of rheumatic illness away from tetracycline to minocycline. Minocycline may benefit rheumatoid arthritis patients through its immunomodulating and immunosuppressive properties. In vitro studies have demonstrated a decreased neutrophil production of reactive oxygen intermediates along with diminished neutrophil chemotaxis and phagocytosis.

    Minocycline has also been shown to reduce the incidence and severity of synovitis in animal models of arthritis. The improvement was independent of minocycline’s effect on collagenase.

    Minocycline has also been shown to increase intracellular calcium concentrations that inhibit T-cells.

    Individuals with the Class II major histocompatibility complex (MHC) DR4 allele seem to be predisposed to developing rheumatoid arthritis.

    The infectious agent probably interacts with this specific antigen in some way to precipitate rheumatoid arthritis. There is strong support for the role of T cells in this interaction.

    So minocycline may suppress rheumatoid arthritis by altering T cell calcium flux and the expression of T cell derived from collagen binding protein. Minocycline produced a suppression of the delayed hypersensitivity in patients with Reiter’s syndrome, and investigators also successfully used minocycline to treat the arthritis and early morning stiffness of Reiter’s syndrome.

    Clinical Studies

    In 1970, investigators at Boston University conducted a small, randomized placebo-controlled trial to determine if tetracycline would treat rheumatoid arthritis. They used 250 mg of tetracycline a day.

    Their study showed no improvement after one year of tetracycline treatment. Several factors could explain their inability to demonstrate any benefits.

    Their study used only 27 patients for a one-year trial, and only 12 received tetracycline, so noncompliance may have been a factor. Additionally, none of the patients had severe arthritis. Patients were excluded from the trial if they were on any anti-remittive therapy.

    Finnish investigators used lymecycline to treat the reactive arthritis in Chlamydia trachomatous infections. Their study compared the effect of the medication in patients with two other reactive arthritis infections: Yersinia and Campylobacter.

    Lymecyline produced a shorter course of illness in the Chlamydia induced arthritis patients, but did not affect the other enteric infections-associated reactive arthritis. The investigators later published findings that suggested lymecycline achieved its effect through non-antimicrobial actions. They speculated it worked by preventing the oxidative activation of collagenase.

    The first trial of minocycline for the treatment of animal and human rheumatoid arthritis was published by Breedveld. In the first published human trial, Breedveld treated 10 patients in an open study for 16 weeks. He used a very high dose of 400 mg per day. Most patients had vestibular side effects resulting from this dose.

    However, all patients showed benefit from the treatment, and all variables of efficacy were significantly improved at the end of the trial.

    Breedveld expanded on his initial study and later observed similar impressive results. This was a 26-week double-blind placebo-controlled randomized trial with minocycline for 80 patients.

    They were given 200 mg twice a day.

    The Ritchie articular index and the number of swollen joints significantly improved (p < 0.05) more in the minocyline group than in the placebo group.

    Investigators in Israel studied 18 patients with severe rheumatoid arthritis for 48 weeks.

    These patients had failed two other DMARD. They were taken off all DMARD agents and given minocycline 100 mg twice a day. Six patients did not complete the study — three withdrew because of lack of improvement, and three had side effects of vertigo or leukopenia.

    All patients completing the study improved. Three had complete remission, three had substantial improvement of greater than 50 percent, and six had moderate improvement of 25 percent in the number of active joints and morning stiffness.

    APPENDIX TWO: Make Certain You are Assessed for Fibromyalgia

    You need to be very sensitive to this condition when you have rheumatoid arthritis as it is frequently a complicating condition. Many times, the pain will be confused with a flare-up of the RA.

    You need to aggressively treat this problem. If it is ignored, the likelihood of successfully treating the arthritis is significantly diminished.

    Fibromyalgia is a very common problem. Some experts believe that five percent of people are affected with it. Over 12 percent of the patients at the Mayo Clinic’s Department of Physical

    Medicine and Rehabilitation have this problem, and it is the third most common diagnosis by rheumatologists in the outpatient setting. Fibromyalgia affects women five times as frequently as men.

    Signs and Symptoms of Fibromyalgia

    One of the main features of fibromyalgia is morning stiffness, fatigue, and multiple areas of tenderness in typical locations. Most people with fibromyalgia complain of pain over many areas of their body, with an average of six to nine locations. Although the pain is frequently described as being “all over,” it is most prominent in the neck, shoulders, elbows, hips, knees, and back.

    Tender points are generally symmetrical and on both sides of the body. The areas of tenderness are usually small (less than an inch in diameter) and deep within the muscle. They are often located in sites that are slightly tender in normal people.

    People with fibromyalgia, however, differ in having increased tenderness at these sites from the average person. Firm palpation with the thumb (just past the point where the nail turns white) over the outside elbow will typically cause a vague sensation of discomfort. Patients with fibromyalgia will experience much more pain and will often withdraw the arm involuntarily.

    More than 70 percent of patients describe their pain as profound aching and stiffness of muscles. Often it is relatively constant from moment to moment, but certain positions or movements may momentarily worsen the pain. Other terms used to describe the pain are “dull” and “numb.”

    Sharp or intermittent pain is relatively uncommon.

    Patients with fibromyalgia also often complain that sudden loud noises worsen their pain.

    The generalized stiffness of fibromyalgia does not diminish with activity, unlike the stiffness of rheumatoid arthritis, which lessens as the day progresses. Despite the lack of abnormal lab tests, patients can suffer considerable discomfort.

    The fatigue is often severe enough to impair activities of work and recreation. Patients commonly experience fatigue on arising and complain of being more fatigued when they wake up than when they went to bed.

    Over 90 percent of patients believe the pain, stiffness, and fatigue are made worse by cold, damp weather. Overexertion, anxiety, and stress are also factors.

    Many find that localized heat, such as hot baths, showers, or heating pads, give them some relief. There is also a tendency for pain to improve in the summer with mild activity, or with rest.

    Some patients will date the onset of their symptoms to some initiating event. This is often an injury, such as a fall, a motor vehicle accident, or a vocational or sports injury. Others find that their symptoms began with a stressful or emotional event, such as a death in the family, a divorce, a job loss, or similar occurrence.

    Pain Location

    Patients with fibromyalgia have pain in at least 11 of the following 18 tender point sites (one on each side of the body):

    1. Base of the skull where the suboccipital muscle inserts
    2. Back of the low neck (anterior intertransverse spaces of C5-C7)
    3. Midpoint of the upper shoulders (trapezius)
    4. On the back in the middle of the scapula
    5. On the chest where the second rib attaches to the breastbone (sternum)
    6. One inch below the outside of each elbow (lateral epicondyle)
    7. Upper outer quadrant of buttocks
    8. Just behind the swelling on the upper leg bone below the hip (trochanteric prominence)
    9. The inside of both knees (medial fat pads proximal to the joint line)

    Fibromyalgia pain sites

    Treatment of Fibromyalgia

    There is a persuasive body of emerging evidence that indicates that patients with fibromyalgia are physically unfit in terms of sustained endurance. Some studies show that exercise can decrease fibromyalgia pain by 75 percent.

    Sleep is also critical to improvement, and many times, improved fitness will also correct the sleep disturbance.

    Normalizing vitamin D levels has also been shown to be helpful to decrease pain as has topical magnesium oil supplementation.

    Allergies, especially to mold, seem to be another common cause of fibromyalgia. There are some simple interventions using techniques called Total Body Modification (TBM). Call 800-243-4826.

    APPENDIX THREE: Antibiotic Therapy with Minocin

    There are three different tetracyclines available: simple tetracycline, doxycycline, or Minocin (minocycline).

    Minocin has a distinct and clear advantage over tetracycline and doxycycline in three important areas:

    1. Extended spectrum of activity
    2. Greater tissue penetrability
    3. Higher and more sustained serum levels

    Bacterial cell membranes contain a lipid layer. One mechanism of building up a resistance to an antibiotic is to produce a thicker lipid layer. This layer makes it difficult for an antibiotic to penetrate. Minocin’s chemical structure makes it the most lipid soluble of all the tetracyclines.

    This difference can clearly be demonstrated when you compare the drugs in the treatment of two common clinical conditions.

    Minocin gives consistently superior clinical results in the treatment of chronic prostatitis. In other studies, Minocin was used to improve 75-85 percent of patients whose acne had become resistant to tetracycline. Strep is also believed to be a contributing cause to many patients with rheumatoid arthritis. Minocin has shown significant activity against treatment of this organism.

    Important Factors to Consider When Using Minocin

    Unlike the other tetracyclines, Minocin tends not to cause yeast infections. Some infectious disease experts even believe that it has a mild anti-yeast activity. Women can be on this medication for several years and not have any vaginal yeast infections. Nevertheless, it would be prudent to take prophylactic oral lactobacillus acidophilus and bifidus preparations.

    This will help to replace the normal intestinal flora that is killed with the Minocin.

    Another advantage of Minocin is that it tends not to sensitize you to the sun. This minimizes your risk of sunburn and increased risk of skin cancer.

    However, you must incorporate several precautions with the use of Minocin.

    Like other tetracyclines, food impairs its absorption. However, the absorption is much less impaired than with other tetracyclines. This is fortunate because some people cannot tolerate Minocin on an empty stomach and have to take it with a meal to avoid GI side effects.

    If you need to take it with a meal, you will still absorb 85 percent of the medication, whereas tetracycline is only 50 percent absorbed. In June of 1990, a pelletized version of Minocin also became available, which improved absorption when taken with meals.

    This form is only available in the non-generic Lederle brand, and is a more than reasonable justification to not substitute for the generic version.

    Clinical experience has shown that many patients will relapse when they switch from the brand name to the generic. In February, 2006 Wyeth sold manufacturing rights of Minocin to Triax Pharmaceuticals (866-488-7429).

    Clinically, it has been documented that it is important to take Lederle brand Minocin as most all generic minocycline are clearly less effective.

    A large percentage of patients will not respond at all, or not do as well with generic non-Lederle minocycline.

    Traditionally it was recommended to only receive the brand name Lederle Minocin. However, there is one generic brand that is acceptable, and that is the brand made by Lederle. The only difference between Lederle generic Minocin and brand name Minocin is the label and the price.

    The problem is finding the Lederle brand generic. Some of my patients have been able to find it at Wal Mart. Since Wal Mart is one of the largest drug chains in the US, this should make the treatment more widely available for a reduced charge.

    Many patients are on NSAID’s that contribute to microulcerations of the stomach, which cause chronic blood loss. It is certainly possible to develop a peptic ulcer contributing to this blood loss.

    In either event, patients are frequently receiving iron supplements to correct their blood counts.

    IT IS IMPERATIVE THAT MINOCIN NOT BE GIVEN WITH IRON!

    Over 85 percent of the dose will bind to the iron and pass through your colon unabsorbed.

    If iron is taken, it should be at least one hour before Minocin, or two hours after.

    A recent, uncommon, complication of Minocin is a cell-mediated hypersensitivity pneumonitis.

    Most patients can start on 100 mg of Minocin every Monday, Wednesday, and Friday evening. Doxycycline can be substituted for patients who cannot afford the more expensive Minocin.

    It is important to not give either medication daily, as this does not seem to provide as great a clinical benefit.

    WARNING: Tetracycline type drugs can cause a permanent yellow-grayish brown discoloration of your teeth.

    This can occur in the last half of pregnancy, and in children up to eight years old. You should not routinely use tetracycline in children.

    If you have severe disease, you can consider increasing the dose to as high as 200 mg three times a week. Aside from the cost of this approach, several problems may result from the higher doses.

    Minocin can cause quite severe nausea and vertigo, but taking the dose at night tends to decrease this problem considerably.

    However, if you take the dose at bedtime, you must swallow the medication with TWO glasses of water. This is to insure that the capsule doesn’t get stuck in your throat. If that occurs, a severe chemical esophagitis can result, which can send you to the emergency room.

    For those physicians who elect to use tetracycline or doxycycline for cost or sensitivity reasons, several methods may help lessen the inevitable secondary yeast overgrowth. Lactobacillus acidophilus will help maintain normal bowel flora and decrease the risk of fungal overgrowth.

    Aggressive avoidance of all sugars, especially those found in non-diet sodas, will also decrease the substrate for the yeast’s growth. Macrolide antibiotics like Biaxin or Zithromax may be used if tetracyclines are contraindicated.

    They would also be used in the three pills a week regimen.

    Clindamycin

    The other drug used to treat rheumatoid arthritis is clindamycin. Dr. Brown’s book discusses the uses of intravenous clindamycin, and it is important to use the IV form of treatment if the disease is severe.

    In my experience nearly all scleroderma patients require a more aggressive stance and use of IV treatment. Scleroderma is a particularly dangerous form of rheumatic illness that should receive aggressive intervention.

    A major problem with the IV form is the cost. The price ranges from $100 to $300 per dose if administered by a home health care agency. However, if purchased directly from Upjohn, significant savings can be had.

    If you have a milder illness, the oral form of clindamycin is preferable.

    With a mild rheumatic illness (the minority of cases), it is even possible to exclude this from your regimen. Initial starting doses for an adult would be a 1,200 mg dose once a week.

    Please note that many people do not seem to tolerate this medication as well as Minocin. The major complaint seems to be a bitter metallic type taste, which lasts about 24 hours after the dose.

    Taking the dose after dinner does seem to help modify this complaint somewhat. If this is a problem, you can lower the dose and gradually increase the dose over a few weeks.

    Concern about the development of C. difficile pseudomembranous enterocolitis as a result of the clindamycin is appropriate. This complication is quite rare at this dosage regimen, but it certainly can occur.

    It is also important to be aware of the possibility of developing a severe and uncontrollable bout of diarrhea. Administration of acidophilus seems to limit this complication by promoting the growth of the healthy gut flora.

    If you have a resistant form of rheumatic illness, intravenous administration should be considered. Generally, weekly doses of 900 mg are administered until clinical improvement is observed.

    This generally occurs within the first 10 doses.

    At that time, the regimen can be decreased to every two weeks with the oral form substituted on the weeks where the IV is not taken.

    What to Do if You Fail to Respond

    The most frequent reason for failure to respond to the protocol is lack of adherence to the dietary guidelines.

    Most people eat too many grains and sugars, which disturbs insulin physiology. It is important that you adhere as strictly as possible to the guidelines.

    A small minority, generally under 15 percent of patients, will fail to respond to the protocol described above, despite rigid adherence to the diet. These individuals should already be on the IV clindamycin.

    It appears that hyaluronic acid, which is a potentiating agent commonly used in the treatment of cancer, may be quite useful in these cases. It seems that hyaluronic acid has very little to no direct toxicity but works in a highly synergistic fashion when administered directly in the IV bag with the clindamycin.

    Hyaluronic acid is also used in orthopedic procedures. The dose is generally from 2 to 10 cc into the IV bag. Hyaluronic acid is not inexpensive, however, as the cost may range up to $10 per cc. You also need to use some caution, as it may precipitate a significant Herxheimer flare reaction.

Strong link found between rheumatoid arthritis and vitamin D deficiency.


New evidence has emerged that vitamin D deficiency might not only be a cause of rheumatoid arthritis but also worsen the severity of the disease.

In a study published in the journal Nutrients in June, researchers from the University of Saskatchewan evaluated the vitamin D status in 116 patients at a community clinic, 60 of them suffering from rheumatic diseases. The researchers found that vitamin D levels were significantly worse in patients suffering from autoimmune rheumatic disease (such as rheumatoid arthritis).

In addition, the researchers found that, among rheumatoid arthritis patients, lower vitamin D levels were directly correlated with more severe symptoms. The effect was so striking that rheumatoid arthoritis patients with low blood levels of vitamin D were actually five times more likely to suffer from active symptoms than patients with higher levels.

Hands-Wrist-Pain-Fingers-Arthritis

An emerging consensus

Rheumatoid arthritis is an autoimmune disorder, meaning that it is characterized by the immune system misidentifying part of the body as a threat and attacking it. In the case of rheumatoid arthritis, the immune system attacks the joints and other bodily tissues.

Vitamin D has been shown to play a critical role in helping regulate the immune system, and low levels have been linked to a higher risk of various autoimmune diseases. For this reason, researchers have suspected for many years that vitamin D might play a role in the development of rheumatoid arthritis. Population studies have supported this hypothesis, such as one published in the journal Environmental Health Perspectives in 2010 which found that women living in the northeastern United States were significantly more likely to develop rheumatoid arthritis than women living in places that get more year-round sunshine.

The body produces its own vitamin D when the skin is exposed to ultraviolet radiation from sunlight, so overall levels of vitamin D deficiency are lower in regions closer to the equator.

A study published in the journal Arthritis and Rheumatism in 2004 suggests that high levels of dietary vitamin D may also help prevent the development of rheumatoid arthritis. The researchers analyzed data from nearly 30,000 women between the ages of 55 and 69 who had participated in the Iowa Women’s Health Study and had been followed for 11 years. Study participants were periodically questioned about their health status, eating habits and use of nutritional supplements. Over the course of the decade-long study, 152 of the participants were diagnosed with rheumatoid arthritis.

The researchers found that women with the highest dietary intake of vitamin D were the least likely to have developed rheumatoid arthritis. In contrast, women whose diet included fewer than 200 International Units of vitamin D per day had a 33 percent higher risk of developing the disease than women whose diets included more. These results remain statistically significant even after adjusting for other potential rheumatoid arthritis risk factors, such as smoking and calcium intake.

Get more sunlight

Although certain foods are enriched with vitamin D and the vitamin can also be taken in supplement form, getting more sunlight is still the safest and most effective way to increase your body’s levels of this powerful nutrient. Doctors say that your body can produce all the vitamin D it needs from just 15 to 30 minutes per day of skin on the face and hands (without sunscreen) for lighter skinned people, with more time needed for people with darker skin.

And it’s not just for reducing your risk of rheumatoid arthritis. Higher levels of vitamin D have been linked to lower rates of various autoimmune diseases, as well as heart disease, diabetes and cancer.

Therapies for Active Rheumatoid Arthritis after Methotrexate Failure.


BACKGROUND

Few blinded trials have compared conventional therapy consisting of a combination of disease-modifying antirheumatic drugs with biologic agents in patients with rheumatoid arthritis who have active disease despite treatment with methotrexate — a common scenario in the management of rheumatoid arthritis.

METHODS

We conducted a 48-week, double-blind, noninferiority trial in which we randomly assigned 353 participants with rheumatoid arthritis who had active disease despite methotrexate therapy to a triple regimen of disease-modifying antirheumatic drugs (methotrexate, sulfasalazine, and hydroxychloroquine) or etanercept plus methotrexate. Patients who did not have an improvement at 24 weeks according to a prespecified threshold were switched in a blinded fashion to the other therapy. The primary outcome was improvement in the Disease Activity Score for 28-joint counts (DAS28, with scores ranging from 2 to 10 and higher scores indicating more disease activity) at week 48.

RESULTS

Both groups had significant improvement over the course of the first 24 weeks (P=0.001 for the comparison with baseline). A total of 27% of participants in each group required a switch in treatment at 24 weeks. Participants in both groups who switched therapies had improvement after switching (P<0.001), and the response after switching did not differ significantly between the two groups (P=0.08). The change between baseline and 48 weeks in the DAS28 was similar in the two groups (−2.1 with triple therapy and −2.3 with etanercept and methotrexate, P=0.26); triple therapy was noninferior to etanercept and methotrexate, since the 95% upper confidence limit of 0.41 for the difference in change in DAS28 was below the margin for noninferiority of 0.6 (P=0.002). There were no significant between-group differences in secondary outcomes, including radiographic progression, pain, and health-related quality of life, or in major adverse events associated with the medications.

CONCLUSIONS

With respect to clinical benefit, triple therapy, with sulfasalazine and hydroxychloroquine added to methotrexate, was noninferior to etanercept plus methotrexate in patients with rheumatoid arthritis who had active disease despite methotrexate therapy.

Source: NEJM